Benzo[a]phenoxazines: A new group of potent P-glycoprotein inhibitors

In Vivo

Volumn 20, Issue 1, 2006, Pages 109-114

  Wesolowska, Olga ^a   Molnar, Joseph ^b   Westman, Gunnar ^c   Samuelsson, Kristin ^d   Kawase, Masami ^e   Ocsovszki, Imre ^b   Motohashi, Noboru ^f   Michalak, Krystyna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZEGED   (Hungary)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e JOSAI UNIVERSITY   (Japan)

^f MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Flow cytometry; Multidrug resistance; P glycoprotein; Phenoxazine derivatives

Indexed keywords

1 HYDROXYBENZO[A]PHENOXAZIN 9 ONE; 10 ACETYLPHENOXAZINE; 2 HYDROXYBENZO[A]PHENOXAZIN 9 ONE; 2 PIPERIDINOPHENOXAZIN 3 ONE; 9H BENZO[A]PHENOXAZIN 9 ONE; BENZO[A]PHENOXAZINE DERIVATIVE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; NEW DRUG; PHENOXAZINE; PHENOXAZINE DERIVATIVE; RESORUFIN; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FLOW CYTOMETRY; LYMPHOMA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; T CELL LYMPHOMA;

EID: 30844465481     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Goldberg IH and Friedman PA: Antibiotics and nucleic acids. Annu Rev Biochem 40: 775-810, 1971.
2. Motohashi N, Mitscher JA and Meyer R: Potential antitumor phenoxazines. Med Res Rev 11: 239-294, 1991.
3. Shimamoto T, Tomoda A, Ishida R and Ohyashiki K: Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivo. Clin Cancer Res 7: 704-708, 2001.
4. Nakada T, Isaka K, Nishi H, Osakabe Y, Shimamoto T, Ohyashiki K, Tomoda A and Takayama M: A novel phenoxazine derivative suppresses proliferation of human endometrial adenocarcinoma cell lines, inducing G2M accumulation and apoptosis. Oncol Rep 10: 1171-1176, 2003.
5. Gao S, Takano T, Sada K, He J, Noda C, Hori-Tamura N, Tomoda A and Yamamura H: A novel phenoxazine derivative suppresses surface IgM expression in DT40 B cell line. Br J Pharmacol 137: 749-755, 2002.
6. Shimizu S, Suzuki M, Tomoda A, Arai S, Taguchi H, Hanawa T and Kamiya S: Phenoxazine compounds produced by the reactions with bovine hemoglobin show antimicrobial activity against non-tuberculosis mycobacteria. Tohoku J Exp Med 203: 47-52, 2004.
7. Iwata A, Yamaguchi T, Sato K, Izumi R and Tomoda A: Antiviral activity of 2-amino-4,4α-dihydro-4α-7-dimethyl-3H-phenoxazine-3-one on poliovirus. Tohoku J Exp Med 200: 161-165, 2003.
8. Azuine MA, Tokuda H, Takayasu J, Enjyo F, Mukainaka T, Konoshima T, Nishino H and Kapadia GJ: Cancer chemopreventive effect of phenothiazines and related triheterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models. Pharmacol Res 49: 161-169, 2004.
9. Thimmaiah KN, Horton JY, Qian XD, Beck WT, Houghton JA and Houghton PJ: Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. Cancer Commun 2: 249-259, 1990.
10. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1999.
11. Ramu A and Ramu N: Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30: 165-173, 1992.
12. Molnar J, Hever A, Fakla I, Fischer J, Ocsovski I and Aszalos A: Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res 17: 481-486, 1997.
13. Wesolowska O, Molnar J, Motohashi N and Michalak K: Inhibition of P-glycoprotein transport function by N-acylphenothiazines. Anticancer Res 22: 2863-2868, 2002.
14. Thimmaiah KN, Horton JK, Seshadri R, Israel M, Houghton JA, Harwood FC and Houghton PJ: Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells. J Med Chem 35: 3358-3364, 1992.
15. Horton JK, Thimmaiah KN, Harwood FC, Kuttesch JF and Houghton PJ: Pharmacological characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells. Mol Pharmacol 44: 552-559, 1993.
16. Thimmaiah KN, Jayashree BS, Germain GS, Houghton PJ and Horton JK: Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells. Oncol Res 10: 29-41, 1998.
17. Eregowda GB, Krishnegowda G, Kalpana HN, Channu BC, Dass C, Horton JK, Houghton PJ and Thimmaiah KN: Structural requirements for activity of phenoxazines for reversal of drug resistance in cancer cells. Asian J Chem 11: 878-905, 1999.
18. Eregowda GB, Kalpana HN, Hedge R and Thimmaiah KN: Synthesis and analysis of structural features of phenoxazine analogues needed to reverse vinblastine resistance in multidrug resistant (MDR) cancer cells. Indian J Chem 39B: 243-259, 2000.
19. Ford JA, Prozialeck WC and Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115, 1989.
20. Channu BC, Kalpana HN, Eregowda GB, Dass C, Houghton PJ and Thimmaiah KN: Interaction of substituted phenoxazine chemosensitizers with bovine serum albumin. J Pharm Biomed Anal 21: 775-785, 1999.
21. Kalpana HN, Channu BC, Dass C. Dass C, Houghton PJ and Thimmaiah KN: Hydrophobic interactions of phenoxazine modulators with bovine serum albumin. Proc Indian Acad Sci 112: 51-61, 2000.
22. Kehrmann F and Saager A: Nitro derivatives of phenoxazines and thionine violet in oxazine series. Chem Ber 36: 475-484, 1903.
23. Fischer O and Hepp E: Some naphthophenoxazine derivatives. Chem Ber 36: 1807-1815, 1903.
24. Dostal V and Ruzicka E: Preparation of 2-hydroxybenzo[a]phenoxazin-9-one and its derivatives. Acta Univ Palacki Olomuc Fac Rerurn Nat 45(Chemica 14): 129-135, 1974.
25. Postovskii IY, Pashkevich KI and Afanaseva GB: Research on the chemistry of phenoxazines. VIII. Synthesis of amino derivatives of phenoxazinones. Chem Heterocyclic Comp USSR 81: 403-405, 1974.
26. Pastan I, Gottesman MM, Ueda Y, Lovelace E, Rutheford AV and Willingham MC: A retrovirus carrying an MDR-1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Sci USA 85: 4486-4490, 1988.
27. Weaver JL, Szabo G, Pine PS, Gottesman MM, Goldenberg S and Aszalos A: The effect of ion channel blockers, immunosupressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 54: 456-461, 1993.
28. Ghose AK, Pritchett A and Crippen GM: Atomic physicochemical parameters for three dimensional structure activity relationships III: modelling hydrophobic interactions. J Comput Chem 9: 80-90, 1988.
29. Klopman G, Shi LM and Ramu A: Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52: 323-334, 1997.
30. Zamora JM, Pearce HL and Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462, 1988.